Drug Profile
RET kinase companion diagnostic - Thermo Fisher Scientific
Alternative Names: Oncomine Dx Target Test - Thermo Fisher Scientific; Oncomine Dx Target Test Multi-CDx - Thermo Fisher Scientific; Pralsetinib companion diagnostic - Thermo Fisher Scientific; Rearranged during transfection (RET) kinase companion diagnostic - Thermo Fisher Scientific; Selpercatinib companion diagnostic - Thermo Fisher ScientificLatest Information Update: 28 Oct 2022
Price :
$50
*
At a glance
- Originator Thermo Fisher Scientific
- Developer Blueprint Medicines; Thermo Fisher Scientific
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Non-small cell lung cancer
- No development reported Thyroid cancer
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for clinical-Phase-Unknown development in Thyroid-cancer(Diagnosis) in USA
- 10 Sep 2021 Registered for Non-small cell lung cancer (Diagnosis) in Japan (unspecified route)
- 08 Sep 2020 Registered for Non-small cell lung cancer (Diagnosis, Metastatic disease) in USA (unspecified route)